Rhythm Pharmaceuticals Inc RYTM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 05/10/24 EDT

39.14UNCH (UNCH)

Volume

16,937

39.14

+0.64 (+1.66%)

Volume

354,777

52 week range

15.50 - 52.57

Open39.00
Day High39.60
Day Low38.14
Prev Close38.50
52 Week High52.57
52 Week High Date02/12/24
52 Week Low15.50
52 Week Low Date07/06/23

Key Stats

Market Cap2.386B
Shares Out60.97M
10 Day Average Volume0.75M
Dividend-
Dividend Yield-
Beta1.96
YTD % Change-14.86

KEY STATS

Open39.00
Day High39.60
Day Low38.14
Prev Close38.50
52 Week High52.57
52 Week High Date02/12/24
52 Week Low15.50
52 Week Low Date07/06/23
Market Cap2.386B
Shares Out60.97M
10 Day Average Volume0.75M
Dividend-
Dividend Yield-
Beta1.96
YTD % Change-14.86

RATIOS/PROFITABILITY

EPS (TTM)-4.64
P/E (TTM)-8.44
Fwd P/E (NTM)-9.10
EBITDA (TTM)-270.015M
ROE (TTM)-194.69%
Revenue (TTM)91.925M
Gross Margin (TTM)88.37%
Net Margin (TTM)-297.93%
Debt To Equity (MRQ)174.35%

EVENTS

Earnings Date07/30/2024(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Rhythm Pharmaceuticals Inc

Lightning Round: It's a great time to sell Aspin Aerogels, says Jim CramerApril 18, 2024CNBC.com
Cramer's Lighting Round: Sell Aspen AerogelsApril 18, 2024CNBC.com

Content From Our Affiliates

Steady Performance and Promising European Growth Justify Buy Rating for Rhythm PharmaceuticalsMay 8, 2024TipRanks
Rhythm Pharmaceuticals downgraded at BofA on less steep uptake for ImcivreeMay 8, 2024TipRanks
Rhythm Pharmaceuticals downgraded to Neutral from Buy at BofAMay 8, 2024TipRanks
Buy Rating Affirmed: Rhythm Pharmaceuticals’ Growth and Clinical Advancements Fuel OptimismMay 7, 2024TipRanks
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business UpdateMay 7, 2024TipRanks

Profile

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or...

David Meeker M.D.

Chairman of the Board, President, Chief Executive Officer

Hunter Smith

Chief Financial Officer, Treasurer

Yann Mazabraud

Executive Vice President, Head of International

Jennifer Chien

Executive Vice President, Head of North America

Address

222 Berkeley Street, 12th Floor Boston

Boston, MA

02116

United States

http://www.rhythmtx.com

Top Peers

SYMBOL	LAST	CHG	%CHG
ACLX Arcellx Inc	49.74	-2.99	-5.67%
MRUS Merus NV	44.52	-0.60	-1.33%
KYMR Kymera Therapeutics Inc	37.90	-0.71	-1.84%
MLTX MoonLake Immunotherapeutics	40.92	-1.05	-2.50%
ARVN Arvinas Inc	31.44	-0.51	-1.60%